Stay updated on Amivantamab & Lazertinib in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Amivantamab & Lazertinib in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Amivantamab & Lazertinib in NSCLC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update or revision in the study details related to the effectiveness of the study drugs, amivantamab and lazertinib, in treating metastatic NSCLC with an EGFR mutation.
    Difference
    0.1%
    Check dated 2024-06-06T14:29:08.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to provide a detailed description of eligibility criteria for clinical research, including examples such as a person's general health condition or prior treatments. The new text also directs users to 'Learn About Studies' for general information about clinical research.
    Difference
    60%
    Check dated 2024-05-22T21:01:33.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:33:33.000Z thumbnail image

Stay in the know with updates to Amivantamab & Lazertinib in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Amivantamab & Lazertinib in NSCLC Clinical Trial page.